MedPath

Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy

Not Applicable
Conditions
Liver Neoplasms
Interventions
Other: Remote ischemia precondition
Other: None remote ischemia precondition
Registration Number
NCT02168608
Lead Sponsor
Eastern Hepatobiliary Surgery Hospital
Brief Summary

Remote ischemia precondition could protect the liver from ischemia reperfusion injury in patients undergoing hepatectomy.

Detailed Description

Remote ischemia precondition (RIPC) had been proofed beneficial to ischemia reperfusion injury of heart, kidney, liver, brain and spinal cord in experimentation on animals. And the clinical studies of RIPC were mainly focused on heart, RIPC's protection effect on hepatic ischemia reperfusion injury in patients undergoing hepatectomy still remains unknown, So we designed this study to demonstrate the hypotheses.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • No other main organ diseases, American society of Anesthesiologists (ASA) classification Ⅰ-Ⅱ grade
  • Selective hepatectomy, one time hepatic portal occlusion
  • Child-Pugh A
Exclusion Criteria
  • Peripheral vessels diseases
  • Not the same surgical procedure as expected
  • Administered anti-inflammatory drugs as glucocorticoid etc
  • Diagnosed of diabetes
  • History of liver surgery
  • History of hepatic interventional therapy, radiofrequency therapy,radiotherapy and chemotherapy
  • Refuse to join the research
  • Patients with psychopathy
  • Acute infection need antibiotic therapy
  • Hepatic artery or portal vein embolism

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Remote ischemia preconditionRemote ischemia preconditionpatients in this arm accepted RIPC procedure after induction of anesthesia
None remote ischemia preconditionNone remote ischemia preconditionpatients in this arm didn't accept RIPC procedure after induction of anesthesia
Primary Outcome Measures
NameTimeMethod
survival rate30 days postoperatively
Secondary Outcome Measures
NameTimeMethod
alanine aminotransferase (ALT) level in patients' blood7 days postoperatively

Examine the patients's blood sample for ALT level at 7 days postoperatively

aspartic transaminase (AST) level in patients' blood7 days postoperatively

Examine the patients's blood sample for AST level at 7 days postoperatively

complications30 days postoperatively

Number of participants with adverse events within 30 days postoperatively

Trial Locations

Locations (1)

Eastern Hepatobiliary Surgery Hospital

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath